• OPEN AN ACCOUNT
Indian Indices
Sensex
74,764.23 -813.35
( -1.08%)
Global Indices
Nasdaq
52,820.00 -615.25
(-1.15%)
Dow Jones
7,695.68 -43.92
(-0.57%)
Hang Seng
65,089.68 -179.65
(-0.28%)
Nikkei 225
10,664.98 -146.68
(-1.36%)
Forex
USD-INR
94.51 0.08
(0.08%)
EUR-INR
109.83 0.16
(0.15%)
GBP-INR
127.88 0.26
(0.20%)
JPY-INR
0.61 0.01
(0.93%)

EQUITY - MARKET SCREENER

Cipla Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500087
INE059A01026
423.3553764
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
CIPLA
33.7
110515.04
EPS(TTM)
Face Value()
Div & Yield %
40.59
2
0.95
 

USFDA inspects Cipla subsidiary's manufacturing unit in New York
Jul 18,2026

Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT).

The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.